NCT02265679已完成1 期
A Randomized, Double-blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 45
- 主要终点
- Changes from baseline in physical examination
研究概览
简要总结
Safety, tolerability and pharmacokinetics following single doses
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All participants in the study were cystic fibrosis patients:
- •Male or female ≥6 years (pediatrics 6 - 17 years; adult ≥18 years); minimum weight requirement of 20 kg
- •Confirmed diagnosis of CF (positive sweat chloride ≥60 milliequivalents (mEq)/liter (by pilocarpine iontophoresis) and/or a genotype with two identifiable mutations consistent with CF accompanied by one or more clinical features with the CF phenotype
- •Forced expiratory volume in one second (FEV1) >25% predicted (using prediction equation's of Knudson)
- •Clinically stable with no evidence of acute upper or lower respiratory tract infection or current pulmonary exacerbation within 2 weeks of screening
- •Females of child bearing potential needed to have a negative pregnancy test at screening and, if sexually active, had to be willing to use a double-barrier form of contraception for the duration of the study
- •The patient or the patient's legally acceptable representative had to be able to give informed consent in accordance with international conference of harmonization (ICH) good clinical practice (GCP) guidelines and local legislation
- •The patient must be able to swallow the BIIL 284 BS tablet whole
- •Patients taking a chronic medication must be willing to continue this therapy for the entire duration of the study
排除标准
- •Patients with a history of allergy/hypersensitivity (including medication allergy) which is deemed relevant to the trial as judged by the Investigator
- •Patients who had participated in another study with an investigational drug within one month or 6 half-lives (whichever is greater) preceding the screening visit
- •Patients with known substance abuse, including alcohol or drug abuse, within 30 days prior to screening
- •Patients who participated in excessive physical activities (e.g. strenuous sporting events) within 24 hours before the study
- •Female patients who were pregnant or lactating
- •Patients who were unable to comply with breakfast requirements prior to dosing
- •Patients who had received IV, oral or inhaled antibiotics or corticosteroids for a pulmonary exacerbation within 2 weeks of screening
- •Patients who had started a new chronic medication for CF within 2 weeks of screening
- •Patients with documented persistent colonization with B. cepacia (defined as more than one positive culture within the past year)
- •Patients with clinically significant findings on chest x-ray which in the opinion of the Investigator precludes the patient's participation in the trial
- •Patients with oxyhemoglobin saturation in room air <90% by pulse oximetry
- •Patients with hemoglobin <9.0 g/dL; platelets <100x109/L; serum glutamic-oxaloacetic transaminase (ALT) or serum glutamic-pyruvic transaminase (AST) >2 times the upper limit of normal; creatinine >1.8 mg/dL at screening
- •Clinically significant disease or medical condition other than CF or CF-related conditions that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. This includes significant hematological, hepatic, renal, cardiovascular, and neurologic disease. Patients with diabetes may participate if their disease is under good control prior to screening.
研究组 & 干预措施
BIIL 284 BS, low dose in pediatric patients
Experimental
干预措施: BIIL 284 BS, low dose, pediatric patients (Drug)
BIIL 284 BS, medium dose in pediatric patients
Experimental
干预措施: BIIL 284 BS, medium dose, pediatric patients (Drug)
BIIL 284 BS, high dose in pediatric patients
Experimental
干预措施: BIIL 284 BS, high dose, pediatric patients (Drug)
BIIL 284 BS, low dose in adult patients
Experimental
干预措施: BIIL 284 BS, low dose, adult patients (Drug)
BIIL 284 BS, medium dose in adult patients
Experimental
干预措施: BIIL 284 BS, medium dose, adult patients (Drug)
BIIL 284 BS, high dose in adult patients
Experimental
干预措施: BIIL 284 BS, high dose, adult patients (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Changes from baseline in physical examination
时间窗: Pre-dose and up to 5 days after drug administration
Number of patients with clinically relevant changes in vital signs (blood pressure, pulse rate, respiratory rate, body temperature)
时间窗: Pre-dose, up to 5 days after drug administration
Number of patients with clinically relevant changes in laboratory evaluation
时间窗: Pre-dose, up to 5 days after drug administration
Number of patients with adverse events
时间窗: Up to 5 days after drug administration
Changes from baseline in spirometry
时间窗: Pre-dose and up to 5 days after drug administration
Changes from baseline in oximetry
时间窗: Pre-dose and up to 5 days after drug administration
Number of patients with clinically relevant changes in 12-lead ECG
时间窗: Pre-dose, up to 5 days after drug administration
次要结局
- Plasma concentration-time profiles of BIIL 315 ZW in all dose groups(Up to 5 days after drug administration)
- Plasma concentration-time profiles of BIIL 284 BS, BIIL 260 BS and BIIL 304 ZW in medium dose adult and high dose pediatric group(Up to 5 days after drug administration)
- Area under the concentration-time curve of the analytes in plasma (AUC)(Up to 5 days after drug administration)
- Maximum measured concentration of the analytes in plasma (Cmax)(Up to 5 days after drug administration)
- Time from dosing to the maximum concentration of the analytes in plasma (tmax)(Up to 5 days after drug administration)
- Terminal half-life of the analytes in plasma (t1/2)(Up to 5 days after drug administration)
- Total mean residence time of the analytes in the body (MRTtot)(Up to 5 days after drug administration)
- Terminal rate constant of the analytes in plasma (λz)(Up to 5 days after drug administration)
- Apparent clearance of the analytes in plasma following extravascular administration (CL/F)(Up to 5 days after drug administration)
- Apparent volume of distribution during the terminal phase λz following extravascular administration (Vz/F)(Up to 5 days after drug administration)
研究者
相似试验
招募中
1 期
A Phase 1 single and multiple ascending dose study of YA-101 in Healthy SubjectsMultiple System AtrophyACTRN12623001117606Yoda Pharmaceuticals Aus Pty Ltd60
进行中（未招募）
1 期
A single dose study to assess the effect of VAY736 in patients with primary Sjögren’s syndromeEUCTR2013-000250-22-DEovartis Pharma Services AG28
进行中（未招募）
不适用
Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against grass pollen allergyGrass pollen allergyMedDRA version: 18.0Level: LLTClassification code 10036019Term: Pollen allergySystem Organ Class: 100000004870EUCTR2014-005471-88-ESINMUNOTEK, S.L.180
进行中（未招募）
不适用
Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against a mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extractMites allergyMedDRA version: 18.0Level: LLTClassification code 10020419Term: House dust mite allergySystem Organ Class: 100000004870EUCTR2015-000820-27-ESInmunotek, S.L.180
尚未招募
不适用
A Clinical study to evaluate the pain reducing effect of ViphyllinTM in healthy human volunteers.CTRI/2022/05/042912Vidya Herbs Pvt Ltd